Immunic, inc. reports first quarter 2022 financial results and provides corporate update

– top-line data from phase 2 caldose-1 trial of vidofludimus calcium in moderate-to-severe ulcerative colitis expected next month – – part c portion of phase 1 trial of imu-935 in psoriasis patients ongoing; data expected in the second half of 2022 – – current cash and cash equivalents expected to fund immunic into the third quarter of 2023 – – webcast to be held today, may 10, 2022, at 8:00 am et – new york , may 10, 2022 /prnewswire/ -- immunic , inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended march 31, 2022 and provides a corporate update. "the first quarter of 2022 was marked by continued momentum, both financially and within our clinical pipeline programs," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking